Related Experiment Video
Updated: Jan 15, 2026

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
Published on: November 2, 2020
Hypertrophic Cardiomyopathy: Current Perspectives
Dhruvil Patel1, Ruchika Bhargav1, Aliaa Mousa1
1Department of Cardiology, Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ 08901, USA.
Insights
Hypertrophic cardiomyopathy (HCM) is a genetic heart condition affecting 1 in 200-500 people. This review explores its genetic basis, diagnosis via imaging, and novel therapies beyond traditional treatments.
Area of Science:
- Cardiology
- Genetics
- Pathophysiology
Background:
- Hypertrophic cardiomyopathy (HCM) is a genetic disorder causing left ventricular hypertrophy (LVH).
- Prevalence estimates range from 1 in 200 to 1 in 500 individuals.
- Ongoing research identifies new mutations and pathophysiological mechanisms.
Purpose of the Study:
- To systematically review the genetic and pathophysiological basis of HCM.
- To explore the role of multimodality imaging in diagnosing and risk-stratifying HCM patients.
- To examine contemporary management strategies and novel therapies for HCM.
Main Methods:
- Literature review of genetic and pathophysiological studies on HCM.
- Analysis of multimodality imaging techniques for HCM diagnosis and risk stratification.
- Examination of current and emerging therapeutic strategies for HCM.
Main Results:
- Numerous pathogenic mutations linked to HCM have been identified.
- Multimodality imaging is crucial for accurate diagnosis and risk stratification.
- Novel therapies targeting molecular mechanisms offer new treatment avenues.
Conclusions:
- HCM understanding has evolved, leading to refined definitions and recognition.
- Advanced imaging and genetic insights improve patient management.
- Emerging targeted therapies provide alternatives to traditional interventions like myectomy or septal ablation.
Abstract:
Hypertrophic cardiomyopathy (HCM) is a multifaceted genetic disorder characterized by left ventricular hypertrophy (LVH) in the absence of alternative causes, with an estimated prevalence ranging from 1 in 200 to 1 in 500 individuals. Since HCM was first characterized in 1869, a plethora of pathogenic mutations have been identified, while ongoing research continues to elucidate the various pathophysiological mechanisms present in individuals with HCM. Comprehensive physical examination findings and multimodality imaging techniques have become crucial for accurately diagnosing and risk stratifying HCM patients. Meanwhile, recent advancements in research have contributed to a more refined definition and heightened recognition of HCM, prompting further investigations into targeted therapeutic strategies. This evolution in understanding provides alternative treatment options for patients, moving beyond traditional approaches such as myectomy or septal ablation. This review aims to systematically explore the genetic and pathophysiological underpinnings of HCM, as well as the application of multimodality imaging in identifying patients at risk for sudden cardiac death (SCD). The discussion also examines contemporary management strategies for HCM, specifically highlighting novel therapies targeting the molecular mechanisms involved in this disease.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure II: Pathophysiology
Cardiomyopathy IV: Restrictive Cardiomyopathy

